Aquestive Therapeutics Stock Today
| AQST Stock | USD 3.21 0.10 3.22% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Aquestive Therapeutics is selling for under 3.21 as of the 22nd of March 2025; that is 3.22 percent increase since the beginning of the trading day. The stock's last reported lowest price was 3.01. Aquestive Therapeutics has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of July 2018 | Category Healthcare | Classification Health Care |
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey. The company has 98.87 M outstanding shares of which 9.98 M shares are presently shorted by private and institutional investors with about 4.93 trading days to cover. More on Aquestive Therapeutics
Moving together with Aquestive Stock
Moving against Aquestive Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Aquestive Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Keith Kendall | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Drugs (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Drugs, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAquestive Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aquestive Therapeutics' financial leverage. It provides some insight into what part of Aquestive Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aquestive Therapeutics (AQST) is traded on NASDAQ Exchange in USA. It is located in 30 Technology Drive, Warren, NJ, United States, 07059 and employs 142 people. Aquestive Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 307.49 M. Aquestive Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 98.87 M outstanding shares of which 9.98 M shares are presently shorted by private and institutional investors with about 4.93 trading days to cover.
Aquestive Therapeutics currently holds about 17.7 M in cash with (35.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33.
Check Aquestive Therapeutics Probability Of Bankruptcy
Ownership AllocationAquestive Therapeutics holds a total of 98.87 Million outstanding shares. 30% of Aquestive Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Aquestive Ownership Details
Aquestive Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 736.9 K | |
| Bank Of America Corp | 2024-12-31 | 690.3 K | |
| Essex Investment Management Company, Llc | 2024-12-31 | 623.3 K | |
| Northern Trust Corp | 2024-12-31 | 599.8 K | |
| Pale Fire Capital Se | 2024-12-31 | 525.8 K | |
| Bracebridge Capital, Llc | 2024-12-31 | 459.2 K | |
| Ubs Group Ag | 2024-12-31 | 420.6 K | |
| Woodline Partners Lp | 2024-12-31 | 409.3 K | |
| Stifel Financial Corp | 2024-12-31 | 398.6 K | |
| Bratton Capital Management, L.p. | 2024-12-31 | 9.8 M | |
| Blackrock Inc | 2024-12-31 | 6 M |
Aquestive Therapeutics Historical Income Statement
Aquestive Stock Against Markets
Aquestive Therapeutics Corporate Management
| Carl MD | Chief Officer | Profile | |
| Alexander Schobel | Chief Officer | Profile | |
| BSBA Esq | Sr Counsel | Profile | |
| Kenneth MD | Chief Officer | Profile | |
| Kenneth Marshall | Chief Officer | Profile | |
| Ernest Toth | Chief Officer | Profile | |
| Stephen Wargacki | Senior Development | Profile |
Already Invested in Aquestive Therapeutics?
The danger of trading Aquestive Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aquestive Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aquestive Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aquestive Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.